

Pharmacologic Management of Psychosis in the Primary Care Setting

Lorna Francis, CRNP-PMH

1

Learning Objectives

By the end of this continuing education activity, participants will be able to

- ▶ Compare and contrast first- and second-generation antipsychotic medications based on pharmacologic mechanisms, clinical effectiveness, and adverse effect profiles relevant to outpatient psychosis management.
- ▶ Integrate patient-specific clinical factors including symptom severity, psychiatric and medical comorbidities, adherence risk, and metabolic vulnerability to optimize individualized antipsychotic treatment selection.
- ▶ Apply evidence-based prescribing, titration, and monitoring strategies to enhance medication safety, manage adverse effects, and support long-term metabolic and neurologic health outcomes in outpatient populations.

2

Psychosis: Definition

Psychosis, as defined in clinical practice, is a syndrome marked by irregularities in at least one of five core areas:

- ▶ Delusions-false belief Ex. Believes coworkers are plotting to harm them.
- ▶ Hallucinations-false perception Ex. Hears voices when no one is present
- ▶ Disorganized thought (speech) Ex. Speech jumps between unrelated topics.
- ▶ Grossly Disorganized Behavior - Abnormal behavior/motor activity Ex. Wanders aimlessly or catatonia.
- ▶ Negative Symptoms - Reduced expression/motivation Ex. Flat affect, little speech, and lack of initiative.

3

Symptom Categories



Positive symptoms: Delusions, Hallucinations,(auditory, visual, olfactory, gustatory and tactile), and disorganized thinking/behavior.

Negative symptoms: Reduced emotional and motivational functioning

4

Causes of Psychosis

- ▶ First-episode psychotic disorder
- ▶ Substance-induced (cocaine, amphetamines, cannabis, hallucinogens)
- ▶ Exacerbation of schizophrenia or mood disorders
- ▶ Medical/neurologic triggers (infection, hypoxia, metabolic disturbances, steroid induced)

5

Psychotic Disorder: Assessment

- Psychiatric history: symptom onset, progression, stressors
- Mental status exam: thought content, perception, affect
- Rule out secondary causes: substance, medical
- Functional assessment: social, occupational, self-care

6

Psychotic Disorder: Risk Factors

- Genetic: family history of schizophrenia/bipolar
- Neurodevelopmental: perinatal complications, early cognitive deficits
- Environmental: trauma, social stressors, urban living

7

Key Comparisons

Disorder	Duration	Psychosis	Mood Relationship	Key Point
Brief Psychotic	1 day <1 month	Yes	±	Sudden + full recovery
Schizophreniform	1-6 months	Yes	Minimal	Intermediate phase
Schizophrenia	>6 months	Yes	Not primary	Chronic and functional decline
Schizoaffective	Chronic	Yes	Independent psychosis ≥2 weeks	Psychosis outside mood episode
Delusional	≥1 month	Delusions only	Minimal	No major impairment or disorganization
Mood w/ Psychotic features	Episode-based	Yes	Only during mood episodes	Mood drives symptoms
Postpartum Depression	≤4 weeks	±	Primary	After childbirth
Postpartum Psychosis	Days-2 weeks	Yes	Severe	Emergency

8

FDA-Approved Antipsychotics for Psychosis

First-Generation (Typical)	Second-Generation (Atypical)
Dopamine D₂ Blockers <ul style="list-style-type: none"> Haloperidol Chlorpromazine Perphenazine 	Serotonin-Dopamine Modulation / Novel Mechanisms <ul style="list-style-type: none"> Risperidone Olanzapine Aripiprazole Quetiapine Paliperidone Lurasidone Clozapine
Dopamine D₂ Blockers <ul style="list-style-type: none"> Older, classic agents No new approvals past 5 years 	Newer, novel agents focused here <ul style="list-style-type: none"> ★ Caplyta (2019) ★ Cobenfy (2024) ★ Bysanti (2026)
<ul style="list-style-type: none"> ★ First-Generation = Dopamine D₂ ★ Second-Generation = Atypical 	<p>Recent second-generation approvals focus on reduced movement side effects or novel mechanisms.</p> <ul style="list-style-type: none"> ★ Caplyta (2019) ★ Bysanti (2026) <p>Recent second-generation approvals focus on reduced movement side effects or novel mechanisms.</p>
First-Generation = Dopamine D₂	Second-Generation = Serotonin + Dopamine

9

Mechanisms of Action: Antipsychotics

First-Generation (Typical)	Second-Generation (Atypical)
DOPAMINE D₂ Blockade <ul style="list-style-type: none"> Strong dopamine D₂ blockade in limbic pathway → Positive Symptoms Also blocks motor pathways → Movement Side Effects / EPS 	+ SEROTONIN 5-HT_{2A} Blockade <ul style="list-style-type: none"> + Partial DOPAMINE D₂ Blockade 5-HT_{2A} + dopamine receptor activity → Positive Symptoms 5-HT_{2A} antagonism → may help Negative Symptoms Some new drugs hit muscarinic and other novel targets
DOPAMINE D₂ Blockade <ul style="list-style-type: none"> ★ Minimal serotonin / novel pathway effects Ex: Haloperidol, Chlorpromazine ★ Minimal serotonin / novel pathway effects 	+ Partial DOPAMINE D₂ <ul style="list-style-type: none"> ★ Less EPS risk vs. first-generation Ex: Risperidone, Lumateperone (Caplyta), Cobenfy

10

Delirium

Delirium is an acute disturbance in attention, cognition, and awareness that fluctuates over time. Delirium is characterized by three subtypes: hyperactive, hypoactive, and mixed.

Causes:

- UTI, pneumonia, sepsis, Hypoxia or metabolic imbalance.
- Medications: anticholinergics, opioids, steroids
- Alcohol/benzodiazepine withdrawal
- Renal/hepatic failure

No medications are approved by the U.S. Food and Drug Administration for the treatment of delirium. If pharmacologic therapy is indicated, second-generation antipsychotics such as olanzapine, risperidone, and quetiapine are preferred over haloperidol because of their faster onset of action and fewer adverse effects. Patients hospitalized with prolonged delirium have approximately three times the chance of dying in the following year compared with patients with a quick resolution of delirium or no symptoms; therefore, prevention and early detection should be emphasized.

11

Medical Delirium: Assessment & Treatment

Identify acute cognitive changes, labs, vitals, neuro exam	Treat underlying medical condition (primary treatment)	Supportive care: reorientation, sleep/wake regulation, hydration
Antipsychotics only adjunctive: quetiapine, risperidone low-dose haloperidol	Antipsychotics control behavior but do not treat delirium	

12

Differential Comparison Table

Features	Acute Psychosis	Medical Delirium	Primary PD
Onset	Hours-days	Hours-days	Weeks-months
Course	May fluctuate	Fluctuating, worse at night	Persistent
Consciousness	Usually clear	Altered	Clear
Attention	Usually intact	Impaired	Usually intact
Hallucinations	Auditory	Visual	Auditory
Delusions	Present	May be present	Present
Treatment	Antipsychotics ± supportive	Treat underlying cause ± antipsychotics	Long-term antipsychotics + psychosocial

Psychosis Timeline

Timeline: Brief Psychotic Disorder (< 1 Month) → Schizophreniform Disorder (1-6 Months) → Schizophrenia (≥ 6 Months, Chronic)

13

Approach to Medication Selection

Symptom Severity Preferred	Severe positive symptoms → high-potency D ₂ blockade; negative/cognitive symptoms → atypical
Psychiatric Comorbidities Substance use	Anxiety, depression → atypicals with serotonergic effects; long-acting injectables may help adherence
Medical Comorbidities Hepatic/renal	Cardiovascular disease → avoid high metabolic-risk agents; impairment → dose adjustments
Adherence Risk Schedules	Poor adherence → long-acting injectables, simpler dosing
Metabolic Vulnerability atypicals	Obesity, diabetes, dyslipidemia → choose lower-risk (aripiprazole, lurasidone, lumateperone)

14

Abnormal Involuntary Movement Scale (AIMS)

Instructions: Complete the examination procedure before making ratings. Circle score for each item.

Patient Name:	Date:	None	Mild, may be aware	Mild	Moderate	Severe
Facial and Oral Movements						
1. Muscles of facial expression e.g., movements of forehead, eyebrows, periorbital area, cheeks. Include frowning, blinking, smiling, arching.	0	1	2	3	4	
2. Lips and buccal area e.g., protruding, puckering, smacking.	0	1	2	3	4	
3. Jaw e.g., biting, clenching, clattering, mouth opening, lateral movement.	0	1	2	3	4	
4. Tongue Rate only increase in movement both in and out of mouth, NOT inability to sustain movement.	0	1	2	3	4	
Extremity Movements						
5. Upper limbs, wrists, hands, fingers Include specific movements (i.e., rapid, objectively quantifiable, irregular, spontaneous, isolated movements) if relevant (tremor, complex, perseverative). DO NOT include tremor (i.e., repetitive, regular, rhythmic).	0	1	2	3	4	
6. Lower limbs, knees, ankles, feet e.g., lateral knee movement, foot tapping, heel dropping, foot squaring, inversion and eversion of foot.	0	1	2	3	4	
Trunk Movements						
7. Neck, shoulders, hips e.g., torticollis, twisting, squinting, pathic gyrations.	0	1	2	3	4	
Global Judgments						
8. Severity of abnormal movements	0	1	2	3	4	
9. Interference due to abnormal movements	0	1	2	3	4	
10. Patient's awareness of abnormal movements (rate only patient's report) 0 = aware, no distress; 1 = aware, mild distress; 2 = aware, moderate distress; 3 = aware, severe distress	0	1	2	3	4	
Dental Status						
11. Current problems with teeth and/or dentures?	No	Yes				

15

Mini-Mental State Examination (MMSE)

Purpose: Screen cognitive function, Assess severity & progression of dementia, Track changes over time

Cognitive Domains (30 points)

- Orientation (10 pts):** Time & Place (year, date, city, etc.)
- Registration (3 pts):** Name 3 objects & repeat
- Attention & Calculation (5 pts):** Serial 7s or Spell "WORLD"
- Recall (3 pts):** Recall 3 objects
- Language & Praxis (9 pts):** Naming, Commands, Copying


Score Interpretation: 24-30 Normal, 18-23 Mild, 10-17 Moderate, <10 Severe

Tips: Consider education & culture, Screening tool - Further evaluation needed

16




17



18

Resources



The First Episode Clinic (FEC), part of the University of Maryland, Maryland Psychiatric Research Center (MPRC), and the Maryland Early Intervention Program (MEIP), provides state-of-the-art care to those ages 12 - 35 who are within the first two years of experiencing psychosis.

The goal of EPIC is to provide individuals experiencing an initial psychotic episode with accurate diagnosis and treatment for his or her illness. Licensed clinicians and psychiatrists provide comprehensive and immediate treatment in order to stabilize and reduce psychotic symptoms.

Early Psychosis Intervention Clinic
Community Psychiatry Program
Johns Hopkins Bayview Medical Center
4940 Eastern Avenue, Baltimore, MD 21224

31

Resources

Baltimore City:
Baltimore Crisis Response Center
5124 Greenwich Ave, Baltimore, MD 21229
410-433-5175
BCRI (bcreponse.org)

Baltimore County:
Baltimore County Crisis Response - Santé
410.931.2214
Crisis Response and Intervention - Santé Baltimore County (santebaltimorecounty.org)

Sheppard Pratt
6501 N. Charles Street • Baltimore, MD 21204
410-938-5302
<https://www.sheppardpratt.org/care-finder/psychiatric-urgent-care/>

32

Calvert County:
Crisis Intervention Center
410.257.2216
<https://www.cbhcrisisresponse.org/>

Pathways

Prince Frederick: 301.373.3065 Ext 241

Charles County:
Charles County Department of Health
4545 Crain Highway
White Plains, MD 20695
Phone: 301-609-6900
<https://www.charlescountyhealth.org/mental-health-services-2/>

Pathways
Waldorf: 301.373.3065 Ext 310

33

Frederick County:
Mental Health Association Walk-In Crisis Care Center
340 Montevue Lane, Frederick, MD 21702
301-663-0011
<https://cmha.org/how-we-help/behavioral-health/>

Harford County:
Klein Family Center
802 Baltimore Pike
Bel Air, MD 21014
410-874-0711
<https://www.umms.org/uch/locations/klein-family-center>

Montgomery County:
MidCounty DHHS Building
1301 Piccard Drive,
Rockville, MD 20850
240-777-4000
<https://montgomerycountymd.gov/HHS/Program/Program.aspx?id=646397&HC=57&hrcrisiscenter-p204.html>

34

Prince George's County
Pathways
Upper Marlboro: 240.339.1306
<https://www.pathwaysinc.org/>

St. Mary's County:
Pathways
Hollywood: 301.373.3065 Ext 241
<https://www.oathwaysinc.org/>

Talbot County:
Mid Shore Behavioral Health
28578 Mary's Court, Suite 1
Easton, Maryland 21601
410-770-4801
<https://midshorebehavioralhealth.org/crisis-services/>

For All Seasons:
300 Talbot St. Easton, MD
8221 Teal Dr., Suite 427, Easton, MD
410-822-1018
<https://forallseasonsinc.org/what-we-do-how-we-help/psychiatric-care/>

35